RxDoctor Payments Data

Eram Baig, MD

Psychiatry · Hawthorne, CANPI 1649352121

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 45 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$270
  • Alkermes, Inc.$219
  • Sunovion Pharmaceuticals Inc.$165
  • AbbVie$157
  • Johnson & Johnson$148
  • Otsuka America Pharmaceutical, Inc.$48
  • plus $129 from 4 others

What the payments were for

  • Food & beverage$1,08195%
  • Education$565%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$41,545
Medicare patients
78
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate28$85,480
AristadaAripiprazole Lauroxil19$68,270
Abilify MaintenaAripiprazole22$63,970
AustedoDeutetrabenazine12$63,378
RexultiBrexpiprazole23$34,514
Lurasidone Hcl46$10,456
Aripiprazole99$7,287
Quetiapine Fumarate190$3,841
Clozapine72$3,565
Paliperidone ErPaliperidone11$1,971
Olanzapine91$1,474
Vilazodone Hcl12$1,407
Olanzapine OdtOlanzapine21$1,248
Duloxetine Hcl32$895
Ziprasidone Hcl22$858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$48$98,48345 claims
Johnson & JohnsonInvega Sustenna$148$85,48028 claims
Alkermes, Inc.Aristada$219$68,27019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Hawthorne

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →